跳至主要内容
临床试验/NL-OMON35932
NL-OMON35932招募中4 期

Diarrhea during use of the oral angiogenesis inhibitors sunitinib and sorafenib - Diarrhea during use of sunitinib and sorafenib

Integraal Kankercentrum Oost0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients with renal cell carcinoma, GIST, hepatocellular carcinoma or medullary thyroid carcinoma treated with sunitinib or sorafenib
  • Diarrhea CTC grade >= 1, generated during the use of angiogenesis inhibitor
  • Age >= 18 years
  • Signed informed consent

排除标准

  • Known history of relevant disorders: absorption disorders such as inflammatory bowel disease, celiac disease or lactose intolerance
  • Use of laxatives

研究者

发起方
Integraal Kankercentrum Oost

相似试验